Introduction
============

In developed countries, the demographic trend moves towards a society with populations with increasing percentages of citizens aged 65 years and more.[@B1] In Spain, the geriatric population represents 17% of the total population.[@B2] Consequently, there is a heavy health burden as this population corresponds to more than 70% of the total prescription costs in the Spanish National Health System in 2008.[@B3] In Europe, the amount of healthcare resources used by the older citizens is more than double that consumed by the general population.[@B4]

Chronic diseases and multiple medical conditions predominate in older citizens; consequently, there is a high prevalence of polypharmacy, defined as the use of multiple medications which has been associated with negative health outcomes.[@B5] Pharmacokinetics and pharmacodynamics changes in older people are of much relevance in dose regimes. Lack of awareness of these changes can contribute to inappropriate medicines use, which can cause adverse drug effects. Besides, some of these reactions may be confused with progression of the given pathology or with some typical age-related syndromes.[@B1]

A potentially inappropriate medication (PIM) is assumed when the risk of adverse effects outweighs the expected clinical benefit, especially when a safer or more effective alternative therapy is available for the same condition. PIMs use is a major problem among older people, and may contribute to increased risk of adverse drug effects and to developing drug-drug and drug-disease interactions.[@B6],[@B7]

Appropriate prescribing can be assessed by explicit indicators developed by consensus approaches. The most commonly used explicit criteria to review drug treatments and to identify PIMs are the Beers criteria. This tool includes a list of inappropriate drugs that should be avoided in older patients because of toxicity relating to the agent, too-frequent doses or too-large accumulative daily doses (independent of diagnosis), plus a list of criteria considering diagnoses with possible drug-disease interactions.[@B8] Although the Beers criteria have been applied widely in many studies to define potentially inappropriate medications use in older people, several studies considered that these criteria present a number of serious flaws (e.g., many proscribed drugs are not used in European formularies, inclusion of some drugs is subject to controversy, and the criteria do not contemplate problems involving under-used beneficial medicines) and are of doubtful relevance to routine geriatric pharmacotherapy, especially in European countries.[@B7],[@B9] For these reasons, the new PIP criteria have been devised and validated (STOPP: Screening Tool of Older Persons\' Prescriptions; and START: Screening Tool to Alert to Right Treatment) to detect potential errors in prescribing and the omission of well-indicated medication in the geriatric population.[@B10] Recently, these criteria have been adopted by the European Union Geriatric Medicine Society, and have been translated into several European languages.[@B11],[@B12]

Older residents in nursing homes are often frail, with progressive degenerative health problems and frequent polypharmacy. Their dependency and frequent cognitive impairment undermine their capacity to report adverse drug events. A recent study indicated that living in an institutional setting was associated with an increased risk of PIPs in older citizens with mental co-morbidities admitted to hospitals.[@B13] This highlights the need for regular reviews and adjustments of the treatments taken by this geriatric population. By means of a pharmaceutical care service, pharmacists can help detect potential medication problems and improve medication selection appropriateness in older people.[@B6],[@B14],[@B14]

The aims of this study were to identify firstly PIMs using the Beers and the STOPP criteria and secondly errors of omission using the START criteria in nursing home residents; to compare the utility of these screening tools in measuring PIP in institutionalised older people; to determine the relationship between the number of prescribed drugs and PIPs; and to highlight those drugs that frequently contribute to most PIPs in Spanish nursing home residents.

Methods
=======

A cross-sectional restrospective 6-month study was performed in 2008 with patients aged 65 years and above, who were residents of a nursing home in the Lleida region (Spain). For each resident, medical and prescriptions records were reviewed, and patients were included if they had regular systemic medication prescriptions (including inhaled route medicines) and completed clinical diagnosis records; thus, 81 patients (98% of all the residents) were selected during the study period.

A search of PIPs in residents\' medical charts was done by a pharmacist applying both the Beers and the STOPP-START criteria. The pharmacist was not directly involved in these patients' medical care.

PIPs were identified using the Beers criteria (2003) (independently of diagnoses and considering diagnoses or clinical conditions) and the STOPP-START criteria. The STOPP section includes 65 indicators considered to be PIMs, while the START section has 22 indicators of potentially prescribing omissions in older people. Patients\' diagnoses were obtained from medical charts (and were also verified with prescribed medication and analytical values). A minimum 6 month periodical assessment of each patient\'s clinical conditions was done by the physician. Some residents were assessed with a higher frequency (e.g., measurements of HbA1C and/or fasting glucose levels in diabetics patients were assessed weekly or biweekly depending on diabetes type and insulinotherapy).

Flunitrazepam was also considered a PIM because it is a Benzodiazepine marketed in Spain with similar pharmacological properties to other long-acting benzodiazepines, although it was not explicit on the Beers list.

Age, gender, functional status (the Barthel index[@B16]), mental status (MMSE adapted by Lobo[@B17]) and number of chronically prescribed medications, were also recorded. The study protocol was approved by both the responsible clinician and the residence's administration in charge. Informed consents were not required from participants due to their de-identification and lack of direct involvement.

A descriptive analysis of the results for each criterion was done by measuring not only the number of the subjects with PIPs as identified by each tool, but also the number of inappropriateness criteria identified in each patient. To determine statistical correlations between the number of medicines prescribed, age, gender, mental status, Barthel Index and the PIPs, bivariate correlations for nonparametric data were calculated (Spearman\'s ρ correlation coefficient). The Wilcoxon signed rank test for nonparametric data was used to compare the PIPs using the Beers criteria and STOPP. The Pearson\'s chi-square test was used to compare the occurrence of PIPs between males and females, and Barthel index and MMSE. In all statistical tests, a probability value of \<0.05 was considered significant.

Results
=======

[Table 1](#T1){ref-type="table"} summarises the characteristics of the 81 patients prescribed at least one regular systemically acting medicine in the nursing home. The mean age of the participating residents was 84 (SD=8) years, 63% were female and the majority (70%) of patients were 80 years of age, or more. The mean number of medicines prescribed per residents was 5.1 (SD=2.6), with a total number of 416 medicines prescribed. Polypharmacy (that is, at least 5 chronic prescriptions per patient) was detected in 54% of participants. Most residents displayed a low degree of dependence (Barthel Index ≥60), but 48% presented severe cognitive impairment (MMSE score ≤24).

###### 

Characteristics of the patients

  ----------------------------------------------- -------------
  Age, mean (SD)                                  84 (8)

  Range                                           65-98 years

  Gender                                          63% female\
                                                  (51/81)

  Number of medication prescribed                 416

  Prescription medication per resident (SD)       5.1 (2.6)

  Range                                           1-11

  Barthel index                                   

  Mean (SD)                                       57 (35)\
                                                  Range 0-100

  ≥60 (independence or minor dependence in ADL)   65%

  40-55 (moderate limitation)                     15%

  ≤ 35 (disability or severe limitation in ADL)   20%

  Mini-Mental Status Examination                  

  Mean (SD)                                       21 (12)\
                                                  Range 0-35

  ≥30                                             30%

  25-29 (minor cognitive impairment)              22%

  ≤24 (severe cognitive impairment)               48%

  ADL: activities daily living.                   
  ----------------------------------------------- -------------

After applying all the inappropriateness criteria, 50% of patients used at least one PIM to be avoided (41 patients) with a prevalence of 23% of inappropriate prescriptions. [Table 2](#T2){ref-type="table"} summarises the PIM distribution per patient. The STOPP criteria detected a larger number of patients with any PIM (48%) than the Beers criteria (25%). The STOPP criteria also detected a larger number of patients with two or more PIMs than Beers. Thus, a total of 62% of the patients had any PIP according to the STOPP-START criteria, while 64% of the patients had any PIP when considering all three criteria.

###### 

Number of patients identified with a potential inappropriate medicine (PIMs) according to the Beers and STOPP criteria and a potential prescribing omission (PPOs) by the START criteria in 81 patients.

  Num. patients                   Beers      STOPP      START
  ------------------------------- ---------- ---------- ----------
  One inappropriate               11         22         22
  Two                             8          11         8
  Three                           1          4          4
  4 or more                       \-         2          2
  Patients with any PIM-PPO (%)   20 (25%)   39 (48%)   36 (44%)

According to Beers, independently of diagnosis, the most frequently inappropriate drugs use was: long-acting benzodiazepines (7 patients). When considering a diagnosis in a person with gastric or duodenal ulcers, use of conventional NSAIDs was the most widely prescribed contraindicated drug (4 patients). Overall, the Beers criteria identified 13 PIMs (independently of diagnosis) in 15% of patients. Furthermore, and in relation to disease, the Beers criteria identified 17 PIMs in 19% of patients ([Table 3](#T3){ref-type="table"}). A statistically significant positive correlation was found between the number of medicines prescribed and the number of PIMs detected using the Beers criteria (rs=0.383, P\<0.001). The number of PIMs identified was significantly lower using Beers (7% of total prescriptions in 25% patients) than STOPP (16% of total prescriptions in 48% of patients) (Wilcoxon signed-ranks test Z= -3.775, P\<0.001), despite both containing a similar number of rules.

###### 

Potential inappropriate medicines identified using the Beers criteria.

  ------------------------------------------------------------------------------------------------------------------------ --------------------------------------------- ---
  BEERS CRITERIA: Independent of diagnosis                                                                                                                               

  Amiodarone                                                                                                               1                                             

  Long-acting benzodiazepines                                                                                              7                                              

  \- Diazepam                                                                                                                                                            2

  \- Chlorazepate                                                                                                                                                        4

  \- Flunitrazepam^a^                                                                                                                                                    1

  Long-term long half-life NSAIDs                                                                                          2                                              

  \- Indomethacin                                                                                                                                                        1

  \- Ketorolac                                                                                                                                                           1

  Antidepressant                                                                                                                                                          

  \- Fluoxetine (daily)                                                                                                                                                  2

  Cerebral Vasodilators                                                                                                                                                   

  \- Dihydroergocristine^b^ - Piracetam                                                                                                                                  1

  TOTAL                                                                                                                    13                                             

                                                                                                                                                                          

  BEERS CRITERIA: Considering diagnosis                                                                                                                                  

  Diagnosis                                                                                                                DRUG                                           

  Gastric or duodenal ulcers                                                                                               NSAIDs and aspirin (\>325 mg)                 4

  Bladder outflow obstruction                                                                                              Antidepressant (fluoxetine)                   1

  Stress incontinence                                                                                                      Long-acting benzodiazepines                   3

  Parkinson disease                                                                                                        Conventional antipsychotics                   1

  Depression                                                                                                               Long-term benzodiazepine use                  1

  Syncope or falls                                                                                                         Short-to intermediate acting benzodiazepine   3

  COPD                                                                                                                     Long-acting benzodiazepines (chlorazepate)    1

  Constipation                                                                                                             Calcium channel blockers                      3

  TOTAL                                                                                                                    17                                            

  ^a^Long-acting benzodiazepine not included in the Beers list.\                                                                                                         
  ^b^Beers criteria indicated \"ergot mesyloids\"\                                                                                                                       
  NSAIDs: nonsteroidal anti-inflammatory drugs.\                                                                                                                         
  COPD: Chronic obstructive pulmonary disease.\                                                                                                                          
  Patients\' diagnoses were recorded from medical charts (included analytical values and prescribed pharmacotherapies).\                                                 
  Tendency to falls was assigned if patients had at least two falls in the last year.                                                                                    
  ------------------------------------------------------------------------------------------------------------------------ --------------------------------------------- ---

The number of PIMs identified by STOPP was 66 in 48% of patients. Of the 65 criteria, only 16 identified a PIM. The highest prevalence (22) was related to the central nervous system (15 relating to neuroleptics), followed by drugs for the cardiovascular system (18) ([Table 4](#T4){ref-type="table"}). PIMs of NSAIDs accounted for 13 cases, but they corresponded to seven patients: six with hypertension and one with heart failure. NSAIDs also contributed to two cases of duplicate drug class prescriptions. The Beers criteria considered that NSAIDs were to be avoided with gastric or duodenal ulcers (four patients). In contrast, STOPP did not apply this criterion (E1) for the concurrent use of proton pump inhibitors (PPI), following clinical guideline recommendations, thus allowing treatment to proceed in these four patients. This approach is more flexible than that of the Beers criteria. Besides, STOPP details particular instances where prescription of NSAIDs is potentially inappropriate; e.g., heart failure, hypertension, prolonged treatment for osteoarthritis, gout or chronic renal failure. A statistically significant positive correlation was found between the number of medicines prescribed and the number of PIM calculated using STOPP (rs=0.296, P\<0.01). Besides, a significant positive correlation was found between age and the number of PIM calculated using STOPP (rs=0.256, P\<0.05) but was not significant using the Beers criteria. A higher number of PIMs detected by the STOPP criteria was presented in females than in males (rs=0.230, P\<0.05). In fact, the occurrence of PIMs in females (54.9%) was more frequent than in males (36.7%), although the difference was not statistically significant (Pearson\'s chi-square test).

###### 

Potential inappropriate medicines identified by the STOPP criteria.

  CRITERIA                                                                                                                                                                                           
  ---------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- ----
  A Cardiovascular system                                                                                                                                                                            
  3                                                                      Loop diuretic as first-line monotherapy for hypertension.                                                                   4
  8                                                                      Calcium channel blockers with chronic constipation.                                                                         3
  12                                                                     Aspirin at dose \>150 mg day.                                                                                               6
  13                                                                     Aspirin with no history of coronary, cerebral or peripheral vascular symptoms or occlusive event.                           5
  B Central nervous system and psychotropic drugs                                                                                                                                                    
  7                                                                      Long-term (i.e., \>1 month), long-acting benzodiazepines and benzodiazepines with long-acting metabolites, e.g. diazepam.   7
  8                                                                      Long-term (i.e,. \>1 month) neuroleptics as long-term hypnotics.                                                            14
  9                                                                      Long-term neuroleptics (\>1 month) in those with parkinsonism.                                                              1
  D Respiratory system                                                                                                                                                                               
  3                                                                      Nebulized ipratropium with glaucoma.                                                                                        1
  E Musculoskeletal system                                                                                                                                                                           
  2                                                                      NSAID with moderate--severe hypertension.                                                                                   6
  3                                                                      NSAID with heart failure.                                                                                                   2
  4                                                                      Long-term use of NSAID (\>3 months) for symptom relief of mild osteoarthritis.                                              4
  6                                                                      NSAID with chronic renal failure\*.                                                                                         1
  G Endocrine system                                                                                                                                                                                 
  1                                                                      Glibenclamide or chlorpropamide with Type 2 diabetes mellitus.                                                              3
                                                                         H Drugs that adversely affect fallers                                                                                        
  1                                                                      Benzodiazepines                                                                                                             5
  2                                                                      Neuroleptic drugs.                                                                                                          1
  J Duplicate drug classes                                                                                                                                                                           
                                                                         Any duplicate drug class prescription (two concurrent: NSAIDs, benzodiazepines)                                             3
  TOTAL                                                                  66                                                                                                                          
  \*Serum creatinine \>150 mmol l-1, or estimated GFR 20--50 ml min-1.                                                                                                                               

A statistically significant negative correlation was found between the Barthel Index and the cognitive impairment (MMSE) scores, and the number of PIM when the STOPP criteria were applied (rs= -0.330, P\<0.01, rs= -0.097, P\<0.05, respectively). In fact, for those patients without cognitive impairment, the occurrence of PIMs using the STOPP criteria (27%) was less frequent than in patients with moderate or severe cognitive impairment (50% and 55%, respectively). However, the correlation was not statistically significant (Pearson\'s chi-square test).

The START criteria identified a total of 58 omissions of potentially needed drugs in 44% of patients. The most frequent was lack of calcium and vitamin D supplementation in osteoporosis (15%; 12 patients) ([Table 5](#T5){ref-type="table"}). The cardiovascular system accounted for several problems: statins therapy was omitted in 17% of patients from both the cardiovascular and endocrine perspectives. Among those residents with high risk cardiovascular conditions, 12% did not receive prophylactic treatment with anticoagulants, aspirin or antiplatelet therapy (10 omissions). Overall, the number of potential prescribing omissions corresponding to the cardiovascular system, plus major cardiovascular risk factors (statins and antiplatelet therapy), involved 23% of the patients. Of the 22 START criteria, only 13 identified all the potential omissions. A statistically significant positive correlation was found between the number of medicines prescribed and the number of potential omissions (rs=0.300, P\<0.01). However, the relationships between age or gender or the Barthel Index or the cognitive impairment score (MMSE) and the number of potential omissions were not significant.

###### 

Potential prescribing omissions identified by the START criteria

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  CRITERIA                                                                                                                                                                                                                        
  ---------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- ----
  A Cardiovascular system                                                                                                                                                                                                         

  1 & 2                                                                  Warfarin (Acenocumarol) or Aspirin in the presence of chronic atrial fibrillation (AF).                                                                  7

  5                                                                      Statin therapy with a documented history of coronary, cerebral or peripheral vascular disease,\                                                          6
                                                                         where the patient's functional status remains independent for activities of daily living and life expectancy is \>5years. 6                              

  6                                                                      Angiotensin converting enzyme (ACE) inhibitor with chronic heart failure.                                                                                3

  B Respiratory system                                                                                                                                                                                                            

  1                                                                      Regular inhaled beta 2 agonist or anticholinergic agent for mild to moderate asthma or chronic obstructive pulmonary disease (COPD).                     7

  C Central nervous system                                                                                                                                                                                                        

  1                                                                      L-DOPA in idiopathic Parkinson's disease with definite functional impairment and resultant disability.                                                   1

  2                                                                      Antidepressant drug in the presence of moderate--severe depressive symptoms lasting at least 3 months.                                                   5

  D Gastrointestinal system                                                                                                                                                                                                       

  1                                                                      Proton pump inhibitor with severe gastro-oesophageal acid reflux disease                                                                                 1

  2                                                                      Fibre supplement for chronic, symptomatic diverticular disease with constipation.                                                                        2

  E Musculoskeletal system                                                                                                                                                                                                        

  3                                                                      Calcium and Vitamin D supplement in patients with known osteoporosis.                                                                                    12

  F Endocrine system                                                                                                                                                                                                              

  1                                                                      Metformin with Type 2 diabetes (in the absence of renal impairment\*).                                                                                   3

  3                                                                      Antiplatelet therapy in diabetes mellitus with co-existing major cardiovascular risk factors (hypertension, hypercholesterolaemia, smoking history). 3   3

  4                                                                      Statin therapy in diabetes mellitus if co-existing major cardiovascular risk factors present.                                                            8

  TOTAL Potential prescribing omissions                                  58                                                                                                                                                       

  \*Serum creatinine \>150 mmol l-1, or estimated GFR 20--50 ml min-1.                                                                                                                                                            
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The START criteria were formulated to be used in tandem with STOPP to provide a more complete assessment of PIPs.10 We detected a possible incongruence between two STOPP-START items. When applying the STOPP criteria, we detected three diabetic patients with a PIM in relation to rule A13 (Aspirin use with no history of coronary, cerebral or peripheral vascular symptoms). However, if the physician decided to suppress aspirin prescription according to this PIM rule, when applying the START criteria, we could consider that aspirin had been omitted for these patients in accordance with rule F3 (antiplatelet therapy in diabetes with co-existing major cardiovascular risk factors). For this reason, these three diabetic patients were not considered to receive a PIM according to STOPP rule A13.

Discussion
==========

Inappropriate prescribing is a frequent, serious global health problem in older citizens. This study indicates that the PIM rate among Spanish nursing home residents is high; i.e., 48% with the STOPP criteria, and 25% with the Beers criteria. The prevalence of PIM among nursing home patients, using the Beers criteria, range from 28% to 37% in European studies[@B18],[@B19],[@B20] and are even higher in US studies[@B21],[@B22], showing differences in drug availability and prescribing practices. Spanish data identify a PIM prevalence that ranges from 20% to 35% patients among nursing home residents when applying the Beers criteria[@B23],[@B24], and from a 50% to 65% of the patients with at least one of the STOPP criteria[@B23],[@B25] or even higher rates when the study included additional criteria (low-utility drugs).[@B26] Our study obtained a PIM prevalence of 25% patients with the Beers criteria, although several drugs in the list are not available in Spain, or are rarely prescribed nowadays. The PIM prevalence identified by Beers was similar to the range referred to in other European studies using the Beers criteria.[@B18],[@B19],[@B20] However, comparisons are not easy because different set of criteria are applied and given the various study settings.

Both the STOPP and the Beers criteria contain a similar number of PIM rules. Nevertheless only 11 patients were simultaneously detected by both criteria. The overlap was related to rules about benzodiazepines, neuroleptics, NSAIDs and calcium channel blockers. Beers also detected more patients with PIMs relating to the use of NSAIDs than STOPP because Beers did not consider the concurrent use of PPI (omeprazol), which is a serious shortcoming in this Beers rule.

The PIMs obtained with the STOPP criteria included 48% of our patients, with a lower prevalence that ranges from 50% to 65% patients found in Spanish institutional settings.[@B23],[@B25] The STOPP criteria proved more sensitive for the detection of PIMs than Beers, and STOPP also detected more adverse drugs events causing hospitalisation than Beers.[@B6],[@B27] This suggests that the STOPP criteria may be a more relevant inappropriateness detection tool than the Beers criteria as many avoidance drugs are no longer available in Spain, and some other criteria showed discrepancies with more recent guidelines (i.e., NSAIDs prescription associated with a PPI, as indicated previously).

Almost 60% of the PIMs detected by STOPP involve benzodiazepines, neuroleptics and NSAIDs. Chronic use of benzodiazepines has been described in more than 30% of Spanish elderly women[@B28], and long-acting benzodiazepines are prescribed more than short-acting benzodiazepines among Spanish retired people.[@B29] Long-acting benzodiazepines have been frequently highlighted as inappropriate, particularly concerning the risk of falls and fractures and their contribution to mental deterioration.[@B30],[@B31] Thus, they represent a significant preventable risk for older people\'s health. The prevalence of using inadequate psychotropic drugs in the Spanish institutionalised population was 12.5%, with diazepam as one of the most often prescribed drugs.[@B32] Benzodiazepines use in older people was also one of the most common potential problems identified in many studies.[@B19],[@B25],[@B33],[@B34] Psychotropic medication is extensively used in Australian nursing homes for indications other than schizophrenia.[@B35] Long-acting benzodiazepines, and the simultaneous administration of two psychotropic drugs from the same therapeutic class, were frequently involved in patients with adverse drug reactions admitted to a geriatric hospital.[@B36]

The STOPP criteria were significantly associated with avoidable adverse drug events that caused or contributed to patients\' hospitalization.[@B27] This finding has significant implications for hospital geriatric practice. In nursing homes, some authors have found a correlation between inappropriate medication use (the Beers criteria) and occurrence of an adverse health outcome.[@B21]

By applying the STOPP criteria in our study, three cases of item J (any duplicated drug class prescriptions due to a concurrent use of 2 NSAIDs and 2 benzodiazepines) were detected. This unnecessary drug duplication is one of the problems frequently detected in primary care patients with polypharmacy, together with incorrect dose and therapy duration.[@B37] Potentially inappropriate medication use was associated in our study with the use of multiple medications. Polypharmacy was one of the factors relating to potentially inappropriate medications in a multicenter European study with older patients receiving home care[@B30] and in another Irish primary care study.[@B31]

The START criteria detected clinical situations of potentially inappropriate omissions. The present study found omissions in 44% of patients. Very few studies have applied these criteria in nursing homes, although two recent Spanish studies detected prevalences of 30% and 46% in this setting.[@B23],[@B25] The majority of these omissions involved calcium and vitamin D supplements in osteoporosis, plus statins and low-dose aspirin, similar to other underutilization studies.[@B23],[@B25],[@B39],[@B40] A deficient ingestion of calcium and vitamin D in osteoporosis has been highlighted in antiresorptive therapy. As regards cardiovascular omissions, doubts about the efficacy of statins in very elderly patients can be a reason for the non-prescription of these drugs.[@B41] However, low-dose aspirin in secondary prevention morbidity and mortality has evidenced benefits.[@B42] Several studies have reported a link between an underuse of cardiovascular medicines and adverse health outcomes.[@B43],[@B44]

The STOPP criteria were formulated to be used in tandem with START to provide a more complete assessment of PIMs and prescribing omissions.[@B10] We detected a possible incongruence between two STOPP-START items related to aspirin use (as an antiplatelet agent). In a diabetic patient, a STOPP rule for avoidance of aspirin use (A13) must not overlap the necessity of this medication according to the START rule (F3) of antiplatelet therapy for diabetes with major cardiovascular risk factors, as indicated in the Results section.

In this study, we found a positive relationship between the number of medicines and occurrence of potential omissions. Similar underprescribing correlating to polypharmacy was indicated in a geriatric ward study based on drug therapy omission according to clinical practice guidelines, which showed a higher frequency of underprescribing in drugs advised to prevent cardiovascular diseases. This may mean that polypharmacy can dissuade prescribers from adding more medicines. In contrast, an Irish primary care study based on the START criteria did not find this relationship. Our study did not show a statistically correlation between potential omission and mental status, age or gender.

The present study is not without some methodological limitations. A small sample size and the specific setting with a unique physician limit the results from being generalised. The population was cared for by a non-geriatrician practitioner and comprised patients who are representative of nursing homes (advanced old age, predominance of women and polypharmacy (54% taking at least 5 medicines), and many residents had mental health deterioration with similar characteristics to residents in other nursing home-based studies.[@B25],[@B46] Only pharmacists were involved in the review of prescriptions, lack of complete patient clinical data may limit the full application of tools and can overestimate or underestimate PIPs. This study highlights the possible problems in nursing home patients including a frequently understated aspect of prescribing omission. It ought to be remembered that PIPs detected by explicit criteria cannot be considered a real problem until a clinician judges that individual patient\'s adequacy in his/her exact situation.

Different approaches to improve prescribing among older patients have been undertaken in several settings. Some studies have shown that the positive contribution of pharmacists can help enhance medication management in polypharmacy and older patients, and can improve patient outcomes.[@B7],[@B15],[@B47] Recently, Gallagher and co-workers have shown significant improvements in prescribing appropriateness by applying the STOPP/START criteria as an intervention process in hospitalized older patients.[@B48] Sotoca et al. similarly applied the STOPP/START criteria in nursing home residents, reported PIPs to the responsible physician and obtained a modification of medical prescriptions in 53% of the patients.[@B25] The practical application of the STOPP/START criteria in community pharmacy has not yet been established. These tools may apply to medication reviews when dispensing drugs following pharmaceutical care services with a view to identifying situations which entail alerting nursing home physicians. Nonetheless, lack of complete patient clinical data may limit these criteria from being fully applied in community pharmacy. Besides, criteria could be adapted to primary care computer prescribing systems and be updated in line with new therapeutic evidence. We believe that items have to be also adapted and revalidated for contextual differences among countries. In any case, the systematic application of those explicit criteria will never substitute clinical assessments and clinicians\' judgements. With these tools, however, pharmacists can alert physicians to consider whether medication is a possible cause of adverse health outcomes in older people.

Conclusions
===========

The application of the STOPP-START criteria showed that PIP is a highly prevalent problem in nursing home residents. The STOPP criteria detect a larger number of patients with PIMs than the Beers criteria in this geriatric population. START also detected many patients who did not receive adequate drug treatments for their diseases. Pharmacists can assist in a comprehensive appraisal of older patients' medications using the STOPP-START criteria, which would benefit patients through elimination of potentially inappropriate medication and identification of potential medication omissions to optimize patient care.
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